Entheon Biomedical Corp. ENBIX
CNSX
| 05/31/2026 | 02/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 0.00% | 36.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.00% | 36.13% | |||
| Operating Income | 0.00% | -36.13% | |||
| Income Before Tax | 355.92% | -55.79% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 355.92% | -55.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 355.92% | -55.79% | |||
| EBIT | 0.00% | -36.13% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 482.86% | -2.94% | |||
| Normalized Basic EPS | -40.91% | -4.76% | |||
| EPS Diluted | 482.86% | -2.94% | |||
| Normalized Diluted EPS | -40.91% | -4.76% | |||
| Average Basic Shares Outstanding | -32.75% | 48.72% | |||
| Average Diluted Shares Outstanding | -32.75% | 48.72% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||